CD274 and melanoma: ASCO 2015 Annual Meeting reported that NSCLC patients with PD-L1-negative tumors showed longer progression-free and OS than those with PD-L1-positive (median PFS, 17 months vs 11 months; P = 0.31, median OS, 52 months vs 25 months; P = 0.38; respectively).[34] Increasing data indicate that the PD-1/PD-L1 signaling pathway is related to immune suppression and disease progression, such as melanoma, renal, urothelial, gastric, lung, and colorectal cancer.[35–39] Further studies are needed to identify how PD1/PD-L1 signaling impacts prognosis.